Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

296.42 +2.96 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,784
Open 294.71
Bid (Size) 296.24 (2)
Ask (Size) 296.42 (1)
Prev. Close 293.46
Today's Range 292.35 - 297.86
52wk Range 233.28 - 417.81
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire

Performance

YTD
-17.7%
-17.7%
1 Month
-7.3%
-7.3%
3 Month
-20.2%
-20.2%
6 Month
-15.9%
-15.9%
1 Year
+26.4%
+26.4%

More News

Read More
How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles?
Via Chartmill
2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question
Via StockStory
Earnings Scheduled For February 26, 2025
Via Benzinga
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Quality Investors May Find UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Attractive.
Via Chartmill
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
3 Reasons Investors Watch United Therapeutics (UTHR)
Via StockStory
Topics Stocks
Exposures US Equities
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy
Via Chartmill
2 Value Stocks on Our Watchlist and 1 to Ignore
Via StockStory
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
From United Therapeutics Corporation
Via Business Wire
Why United Therapeutics (UTHR) Stock Is Down Today
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations
Via StockStory
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Via StockStory
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks
Exposures US Equities
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
From United Therapeutics Corporation
Via Business Wire

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 296.42
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 04/24/25 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 13.31B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.